Surge in the number of knee surgeries and arthroplasty and rising awareness about knee surgeries and arthroplasty is expected to drive growth of the knee surgeries and arthroplasty pain management therapeutics market during the forecast period
For instance, in October 2018, Apollo Hospitals, Aragonda conducted a Walkathon event with the main objective of promoting walking for pain free knees. The purpose of the event was to raise awareness about arthritis and how to overcome it with the World Arthritis Day theme. The Apollo Hospitals introduced Total Knee Replacement (TKR) surgeries at its Aragonda unit and since then, as many as 65 surgeries had been done at an affordable cost. Apollo Hospitals, Aragonda created awareness among people about the importance of total knee replacement (TKR) surgeries.
The global knee surgeries and arthroplasty pain management therapeutics market is estimated to be valued at US$ 4,211.7 million in 2022 and expected to exhibit a CAGR of 4.8% over the forecast period (2022-2030).
Figure 1. Global Knee Surgeries and Arthroplasty Pain Management Therapeutics Market Share (%) in Terms of Value, By Region, 2022
Key players operating in the market are focusing on the development and approval of novel therapeutics for the treatment of knee surgeries and arthroplasty pain, which is expected to offer a lucrative opportunity for market players to launch innovative products in the market
For instance, in December 2021, Heron Therapeutics, Inc., a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that the U.S. Food and Drug Administration (FDA) had approved its supplemental New Drug Application (sNDA) for ZYNRELEF (bupivacaine and meloxicam) extended-release solution to significantly expand the indication. ZYNRELEF is now indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.
|Base Year:||2021||Market Size in 2022:||US$ 4,211.7 Mn|
|Historical Data for:||2017 to 2021||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||4.8%||2030 Value Projection:||US$ 6,127.5 Mn|
Pfizer Inc, Allay Therapeutics, Mallinckrodt, Johnson & Johnson, Zydus Cadila Healthcare Ltd., Novartis AG, Purdue Pharma, Delphis Pharmaceutical, Taj Pharmaceuticals Limited, GlaxoSmithKline plc, AbbVie Inc., and Aurobindo Pharma
|Restraints & Challenges:||
Figure 2. Global Knee Surgeries and Arthroplasty Pain Management Therapeutics Market Share (%), by Distribution Channel, 2022
Global Knee Surgeries and Arthroplasty Pain Management Therapeutics Market: Restraint
The growth of the global knee surgeries and arthroplasty pain management therapeutics market may be hampered, owing to product recalls and side effects associated with the use of medication
For instance, in April 2021, A-S Medication Solutions, LLC (ASM), formerly Allscripts Medication Services Group (founded in 1988) – the industry leader in providing complete, end-to-end turnkey, on-site medication dispensing solutions, voluntarily recalled 198,350 bottles of Acetaminophen Extra Strength 500 mg Tablets, 100 ct. bottles contained in Health Essentials Kits distributed by Humana, a for-profit American health insurance company, to its members. This recall was conducted to the consumer level. These over-the-counter (OTC) analgesic products contain an incomplete prescription drug label rather than the required over-the-counter (OTC) drug facts label.
Moreover, some common side effects of COX-2 inhibitors include abdominal pain, headache, nausea, diarrhea, flatulence, and insomnia. COX-2 inhibitors and other Non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk of heart attacks, stroke, and related conditions, which can be fatal. This risk may increase with the duration of use in patients who have underlying risk factors for disease of the heart and blood vessels.
Major players operating in the global knee surgeries and arthroplasty pain management therapeutics market include Pfizer Inc, Allay Therapeutics, Mallinckrodt, Johnson & Johnson, Zydus Cadila Healthcare Ltd., Novartis AG, Purdue Pharma, Delphis Pharmaceutical, Taj Pharmaceuticals Limited, GlaxoSmithKline plc, AbbVie Inc., and Aurobindo Pharma
Many types of medicines are available to help control pain, including opioids, non-steroidal anti-inflammatory drugs (NSAIDs), Acetaminophen, etc. Medications help people feel more comfortable, allowing one to start moving sooner, get the strength back more quickly, and recover from knee surgeries and arthroplasty faster.
Furthermore, increasing number of total knee arthroplasty is expected to drive the market growth over the forecast period
For instance, according to data published by National Center for Biotechnology Information in 2017, the number of total knee arthroplasty is estimated to range between 60,000 and 70,000 per year in Brazil.
Increasing research and development activities by the key players for the development and launch of knee surgeries and arthroplasty pain management drugs are expected to drive the growth of the global knee surgeries and arthroplasty pain management therapeutics market over the forecast period.
For instance, in May 2021, Allay Therapeutics, a clinical-stage biotechnology company, pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, announced the first-ever clinical data showing non-opioid pain relief lasting two weeks after a single administration. The existing post-surgical pain products have shown effectiveness for a maximum of three days after a single dose. The data come from a Phase 1b/2a clinical study of Allay’s first candidate, ATX-101, in development to treat pain after total knee arthroplasty (replacement) or TKA surgery.
Moreover, increasing approval of drug is also expected to boost the market growth. For instance, in march 2020, GlaxoSmithKline Plc. announced that the U.S. Food and Drug Administration had approved Advil Dual Action with Acetaminophen, as an (OTC) over-the-counter product for pain relief. Advil Dual Action gives relief for various symptoms and is the major formulation that merges acetaminophen and ibuprofen, 2 strong ingredients indicated for over-the-counter pain relief that work in different ways.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.